The Aspirin Foundation helps to increase awareness and medical research interest in this vitally important medicine by stimulating the distribution and exchange of information and discussion on all aspects of Aspirin, including current research as well as old and new therapeutic uses for it.
The Aspirin Foundation is guided by an independent International Scientific Advisory Board.
Listen to Prof Jane Armitage, Prof John McNeil, Prof Janusz Jankowski and Prof Mark Hull discuss the ASCEND, ASPREE, AspECT and seAFOod trials.
The International Aspirin Foundation facilitated a discussion of the current evidence for aspirin’s role in cancer prevention and treatment at the Royal Society of Edinburgh on September 21st, 2018. A multidisciplinary group of professors, researchers and clinicians from the U.S, Europe, Asia, and Australia debated how emerging data from recently completed clinical trials will impact on current and future work.
Dr Andrew Chan chaired the meeting in which lively debate took place about follow up of trials for cancer outcomes and areas for future research. Aspirin’s long-term role in the prevention of cancer continues to attract interest and debate. Finding the right population of people to focus prevention efforts and exploring its role for cancer treatment is an area of active research and the opportunity to have the world’s experts on this topic in one room was incredibly valuable and productive for helping move the field forward.
The meeting was supported by Monash University, Melbourne, Australia